Skip to main content

Table 2 Endoscopic examinations

From: Simethicone administration improves gastric cleanness for esophagogastroduodenoscopy: a randomized clinical trial

 

Group 1 (n = 110)

Group 2 (n = 92)

Group 3 (n = 109)

P value

Endoscopic diagnosis, n (%)

    

Chronic atrophic gastritis

6 (5.5)

4(4.3)

10 (9.2)

0.607

Chronic non-atrophic gastritis

89 (80.9)

67 (72.8)

93 (85.3)

Peptic ulcer

5 (4.5)

7 (7.6)

3 (2.8)

Polyp

9 (8.2)

12 (13.0)

3 (2.8)

Carcinoma

1 (0.9)

2 (2.2)

0

Biopsy, n (%)

43 (39.1)

59 (64.1)

55 (50.5)

0.289

Pathological diagnosis for biopsy, n (%)

    

 Chronic atrophic gastritis

4 (3.6)

2 (2.2)

4 (3.7)

 

 Chronic non-atrophic gastritis

22 (20.0)

18 (19.6)

36 (33.0)

 Peptic ulcer

4 (3.6)

5 (5.4)

9 (8.3)

 Adenoma

9 (8.2)

11 (12.0)

3 (2.8)

 Carcinoma

1 (0.9)

2 (2.2)

0

 Intestinal metaplasia

3 (2.7)

9 (9.8)

2 (1.8)

 High-grade intraepithelial neoplasm

0

5 (5.4)

0

 Low-grade intraepithelial neoplasm

0

7 (7.6)

1 (0.9)

Examination time, min, median (range)

8 (2–20)

6 (2–15)

9 (2–25)

0.267

Gastric Cleanness Grade, n (%)

   

< 0.001

 A

19 (17.3)

73 (79.3)

29 (26.6)

 

 B

19 (17.3)

12 (13.0)

41 (37.6)

 

 C

72 (65.5)

7 (7.6)

39 (35.8)